Pharmaceuticals company Granules India announced Q1FY25 results: Revenue from Operations of Q1FY25 stood at Rs 11,799 million, a growth of 20% YoY. Revenue share from the North America increased to 74% in Q1FY25 as compared to 61% in Q1FY24. Decline in Para API and PFI sales volume and price erosion. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 10%, and 76% of revenue from operations respectively for Q1FY25. ROCE is at 19.6% as compared to 9.3% YoY. Net debt stood at Rs 7,941 million and Net debt to EBITDA at 0.77x. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “With our robust quarterly performance, we are back on our planned trajectory after a few setbacks last year. Q1 performance highlights include continued growth in our formulation segment, strong North America business, and product diversification, which offset the Paracetamol API/PFI decline, promising a brighter future driven by our formulations offering and new product pipeline.” Result PDF